New Survey Data Reveals Prior Authorization or Other Utilization Management Strategies, Eligibility Requirements, Annual Maximum as Leading Cost Control Methods A new survey report from the International Foundation of Employee Benefit Plans reveals updated Canadian employer coverage and cost-control mechanisms surrounding glucagon-like peptide-1 (GLP-1) drugs
While you may come across claims online that sermorelin (and similar peptides) can reverse aging, increase muscle mass, or improve athletic performance, these uses are not backed by robust clinical evidence and are considered off-label and potentially unsafe
FDAs 2026 Assessment FDA stated that BPC-157 is not well characterised from a physicochemical perspective and that multiple forms have been marketed under the same common name
C.HooperG
Overall, these findings suggest that Que may counteract cardiovascular disease and oxidative damage
Most individuals inherit susceptibility genes from their parents, although a few cases arise from new mutations not inherited from either parent
